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Abstract
Background: While the psychosocial morbidity of orofacial pain (OFP) is widely rec-
ognized, the differential impact of musculoskeletal, neuropathic and neurovascular 
symptoms on pain and psychosocial function in individuals with and without coexist-
ing OFP conditions is unclear.
Materials and methods: This was a comparative cross-sectional study of 350 con-
secutive patients attending an OFP clinic; 244 completed standardized self-report 
measures of pain experience, mood, and generic and oral health-related quality of life 
(HRQoL). The impact of musculoskeletal, neuropathic and neurovascular symptoms 
on measures was assessed using linear and logistic generalized linear models.
Results: Two hundred patients were diagnosed with a neuropathic condition: 125 
with musculoskeletal pain and 101 with (neurovascular) headache disorders. 23% of 
patients presented with multiple OFP conditions; this was more common in patients 
with neurovascular (62%) than neuropathic (21%) and/or musculoskeletal orofacial 
symptoms (28%). Patients with neurovascular symptoms experienced significantly 
higher levels of pain, evidenced less pain self-efficacy and had poorer overall health. 
Neuropathic OFP was significantly associated with greater psychological and social 
oral health disability. Multiple OFP symptoms were not linked to pain severity or 
psychosocial function, although health scores were worse for patients with neuro-
vascular pain and neuropathic/musculoskeletal symptoms compared with patients 
with only neurovascular symptoms.
Conclusions: The profile and degree of psychosocial morbidity in patients with OFP 
is significantly related to the types of presenting orofacial symptoms. Patients with 
neurovascular pain present with higher pain levels and have poorer health while 
those with neuropathic pain have higher oral functional morbidity; both may require 
more complex multidisciplinary management.
K E Y W O R D S
headache, health-related quality of life, musculoskeletal pain, neuropathic, orofacial pain, 
psychosocial
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1  | INTRODUC TION
Orofacial pain (OFP) is a complex, heterogeneous set of syndromes 
characterized by presentation of pain in the region of the face and oral 
cavity, arising from structures innervated by the trigeminal nerve sys-
tem. Chronic OFP (COFP; ie pain > 3 months) is a common problem, 
with an estimated prevalence in the United Kingdom of 7%.1 COFP is 
often very debilitating, dramatically affecting physical and psycholog-
ical health, social function and economic well-being of individuals.2-6
Broad symptomatic classifications of OFP distinguish between 
musculoskeletal pain (temporomandibular disorders; TMD)—com-
prising disorders of the temporomandibular joint (TMJ) and of the 
musculoskeletal structures (eg masticatory muscles), neuropathic 
syndromes—which include continuous (eg post-traumatic trigeminal 
neuropathy; PTTN) and episodic pain conditions (eg trigeminal neu-
ralgia; TN), and neurovascular disorders—such as migraine and other 
headache disorders.7 Although most patients referred to OFP clinics 
present with musculoskeletal pain and/or neuropathic symptoms, 
neurovascular pain is also frequently encountered.8 Further, both 
clinical and population-based studies suggest a high rate of comorbid 
headache disorders in patients with TMD,9-11 and to a lesser extent, 
in those with neuropathic OFP.8,9,12 This can complicate diagnosis 
and pose considerable management challenges for treating clinicians.
Studies investigating the psychological burden of COFP and (im-
paired) health-related quality of life (HRQoL) in affected patients 
have typically focussed on the effects of specific OFP diagnoses, 
most obviously TMD6 and conditions associated with neuropathic 
pain such as PTTN and TN.2,13 A limited number of studies have di-
rectly compared patients with TMD and orofacial neuropathic pain 
conditions; these observed comparable psychosocial (dys)function, 
although sample sizes were small and only included patients with 
single diagnoses.4,5 Some studies have reported elevated levels of 
depression or disability in TMD patients with comorbid migraine or 
other headache compared with a sole diagnosis of TMD9,14,15 or neu-
rovascular pain only.16 However, very little research has considered 
the differential impact of musculoskeletal, neurovascular and neuro-
pathic symptoms on patient well-being in individuals presenting with 
one or more OFP symptom type.
The objective of the present study was to assess pain severity 
and behaviours, psychological and affective function, and oral and 
generic health in a large sample of OFP patients presenting with 
individual or combined musculoskeletal, neuropathic and/or neuro-
vascular symptoms.
2  | MATERIAL AND METHODS
2.1 | Design and sample
This was a cross-sectional, clinical study. The study sample was 
drawn from 350 consecutive patients attending the OFP Clinic 
at a south London hospital from February 2016-January 2017. 
Patients were aged 18 years and above, presenting with OFP. The 
majority of patients (319, 91.1%) were newly referred patients, while 
31 (8.9%) had previously been referred to (and attended) the ser-
vice. Diagnostic and functional data from subsamples of the patient 
group have been presented elsewhere.8,13 Informed consent for (an-
onymized) questionnaire data to be used for research was obtained 
from all patients and ethical approval for the study provided by the 
National Research Ethics Service Committee, London Dulwich (No. 
15/L0/1108).
2.2 | Clinical examination and diagnosis
Clinical examination of the patients was performed by trained cli-
nicians in OFP with assessment by a neurologist when required. 
Diagnoses related to neuropathic and neurovascular pain were made 
according to the International Classification of Headache Disorders-
III,17 while all TMD diagnoses were made using the Diagnostic 
Criteria for Temporomandibular Disorders.18 Data for patients were 
collected prospectively and included sociodemographic information, 
diagnoses and clinical profile.
2.3 | Measures of pain, psychological 
function and HRQoL
Patients were asked to provide a 0-10 visual analogue scale (VAS) 
rating of pain severity at the time of consultation and complete a 
number of self-report, standardized questionnaires intended to 
measure affective function and HRQoL at their clinic appointment 
or electronically via IMPARTS (an initiative funded by King's Health 
Partners to “integrate mental and physical healthcare in research, 
training and clinical services”).
Anxiety was measured using the 7-item Generalized Anxiety 
Disorder-7 (GAD-7)19 scale, a reliable and valid measure of anxiety in 
primary care, the general population and secondary care, while the 
9-item depression module from the Patient Health Questionnaire 
(PHQ-9),20 a well validated and widely used screening and severity 
measure for depressive symptomatology (including suicidal ideation) 
in primary care and physically ill populations in secondary care, was 
also employed. On both scales, ordinal frequency response catego-
ries for each item (symptom) ranged from 0 (“not at all”) to 3 (“nearly 
every day”), with a total score range of 0-21 for GAD-7 and 0-27 for 
PHQ-9. IMPARTS patients (n = 41) only completed all questionnaire 
items if they responded affirmatively to either of the initial two items 
(ie scored ≥ 2); 24 (GAD-7) and 25 (PHQ-9) patients did not, and 
as such, their data were not considered in analyses of (continuous) 
GAD-7 and PHQ-9 scores.
Oral health was assessed with the Oral Health Impact Profile-14 
(OHIP-14),21 a validated 14-item scale that includes seven concep-
tual dimensions of oral HRQoL. Each item has 5 frequency response 
categories (ranging from 0 for “never” to 4 for “very often”), and 
the measure allows for a total summative severity (0-56) and ex-
tent scores (number of items with “often” or “very often” responses) 
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to be calculated as well as summative scores for each dimension. 
Generic HRQoL was examined using the EQ-5D-5L,22 a health sta-
tus questionnaire comprising five domains (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression), each measured 
on a 5-point ordinal scale (ranging from 0 for “no problems” to 4 
for “extreme problems”), yielding an overall health state valuation 
(ranging from −0.285 for “extreme problems in all domains” to 1.000 
for “no problems in any domain”) derived from an English popula-
tion-normed value set.23 Patients also self-rated their “health today” 
on a 0-100 (“worst health”-to-“best health”) vertical (EQ-)VAS.
Patients who reported experiencing OFP at the time of consul-
tation were asked to complete measures gauging pain experience 
and behaviours. Specifically, the degree of confidence patients has 
in performing activities across different areas (eg work, leisure) 
while in pain was assessed with the 10-item Pain Self-Efficacy 
Questionnaire (PSEQ).24 Responses were scored on a 7-point ordinal 
scale ranging from 0 (“not at all confident”) to 6 (“completely confi-
dent”) for each item, with a total score range of 0-60. The 13-item 
Pain Catastrophizing Scale (PCS)25 was employed to assess patients’ 
tendency to attend to pain stimuli, overestimate their threat value 
and underestimate the ability to handle that threat. Items were rated 
on a 5-point ordinal rating scale ranging from 0 (“not at all”) to 4 (“all 
the time”), yielding a total score ranging from 0 to 52.
2.4 | Data analysis
The relationship of symptom type with demographic and clinical vari-
ables and impact on pain-related, psychosocial and HRQoL indicators 
were calculated using generalized linear models (GLM) with linear or 
logistic models according to (response) variable of interest; magni-
tudes of effects were described by (unstandardized) beta (B) values 
and odds ratios (OR), respectively, with 95% confidence intervals (CI) 
provided for each. Post hoc tests and tests involving dichotomous de-
pendent variables were administered using chi-square for categorical 
variables and univariate analysis of (co-)variance (AN(C)OVA) for con-
tinuous variables. Where continuous data deviated markedly from a 
Gaussian distribution, bootstrapping (bias-corrected and accelerated; 
based on 2000 bootstrap samples) was employed to calculate CI and 
associated P values. To control for possible type I errors due to multi-
ple tests of associations, the false discovery rate (FDR) approach was 
applied to the set of regression models and (post hoc) tests concern-
ing OHIP-14 subscales, with control set to 5%.26 Otherwise, the crite-
rion for statistical significance was set at P < .05. Statistical analyses 
were completed with SPSS (IBM, version 25.0).
3  | RESULTS
3.1 | Sociodemographic and clinical data
A little under three-quarters of patients were female with a wide 
range of ages (18-80 years), averaging just under 50 years old 
(Table 1). Time since symptom onset varied widely, although almost 
all (295, 95.2%) had experienced OFP symptoms for 3 months or 
longer. The mandibular and maxillary divisions were most commonly 
affected with symptoms lateralized in a little under three-quarters 
of patients. More than 200 patients (201, 58.8%) presented with 
neuropathic orofacial symptoms—just over half of these had PTTN, 
reflecting the speciality of the clinic. Smaller numbers presented 
with musculoskeletal orofacial symptoms (most receiving a diagno-
sis of Myalgia or TMJ Disc Displacement with/without reduction) 
and neurovascular symptoms (most commonly Migraine or Other 
primary/secondary headache syndromes). Notably, 5 (1.4%) patients 
had a diagnosis of idiopathic persistent orofacial pain and another 
4 (1.1%) had no confirmed diagnosis; these patients were excluded 
from further analyses.
3.2 | Orofacial pain symptoms
Almost one in four patients (77, 22.5%) presented with more than 
one (broad) type of orofacial symptom (Figure 1); this occurred more 
often in patients with neurovascular (63/101, 62.4%) than muscu-
loskeletal (57/125, 45.6%; P = .001) or neuropathic pain (42/201, 
20.9%; P = .001). Forty-three (42.6%) patients with neurovascular 
pain also had musculoskeletal symptoms, while only 28 (27.7%) had 
concurrent neuropathic symptoms.
There was no relationship between presence of any one symp-
tom type with gender, time since onset or comorbid (non-pain) 
medical conditions (P > .054), although patients with neuropathic 
symptoms tended to be older, B = 5.85, CI = 1.50,10.20, P = .008, 
and presence of TMD symptoms was significantly associated with 
(comorbid) chronic body pain, OR = 2.38, CI = 1.15,4.89, P = .019.
Approximately 70% (244, 70.9%) of patients with a diagnosed 
neuropathic, musculoskeletal and/or neurovascular orofacial condi-
tion(s) completed one or more functional measures. Non-completion 
of questionnaires was due to time constraints in the clinic itself and 
was not related to age, gender, division affected, symptom laterality 
or OFP symptom type (Table 1; for all comparisons between com-
pleters and non-completers, P > .115).
3.3 | Pain severity, psychological 
function and HRQoL
Psychosocial data for the patient sample are shown in Table 2. More 
than 70% (176, 72.4%) reported experiencing OFP at the time of 
consultation, with almost two-thirds of the sample presenting with 
moderate (101, 43.3%) or severe pain (49, 21.0%). PHQ-9 and GAD-7 
scores varied widely, with 29.5% and 18.6% reporting depression and 
anxiety symptom levels that were moderate or severe (>10), respec-
tively. Mean OHIP-14 severity suggested poor oral health relative to 
the United Kingdom dentate population, with more than two-thirds 
of patients (67.2%) scoring above the upper 90th percentile value 
(17).27 Physical pain, psychological discomfort (self-conscious, tense) 
     |  541SMITH eT al.
TA B L E  1   Sociodemographic and clinical information for patients attending the orofacial pain clinic. Values represent frequency 
(percentage) unless otherwise stated
All (n = 350) Questionnaire completers (n = 249)
Gender (Female) 256 (73.1) 180 (72.3)
Age (Mean years, (SD)) 48.5 (14.1) 49.0 (14.2)
Time since onset (median months (range)) 18 (1-420) 18 (1-396)
Site affected
Ophthalmic division (V1) 64 (18.7) 43 (17.7)
Maxillary division (V2) 136 (39.8) 95 (39.1)
Mandibular division (V3) 157 (45.9) 111 (45.7)
Other (eg pre-auricle) 120 (35.1) 84 (34.6)
More than one site affected 107 (31.3) 71 (29.2)
Symptom laterality
Left only 129 (38.5) 90 (37.3)
Right only 117 (34.9) 88 (36.5)
Both left and right 89 (26.6) 63 (26.1)
OFP diagnosis
Neuropathic pain
Post-traumatic Trigeminal Neuropathy 111 (31.7) 75 (30.1)
Persistent Dento-Alveolar Pain 2 31 (8.9) 24 (9.6)
Spontaneous Neuropathy 20 (5.7) 13 (5.2)
Persistent Dento-Alveolar Pain 1 2 (0.6) 2 (0.8)
Burning Mouth Syndrome 11 (3.1) 9 (3.6)
Trigeminal Neuralgia Classical 16 (4.6) 14 (5.6)
Trigeminal Neuralgia Non-classical 17 (4.9) 11 (4.4)
Occipital Neuralgia 10 (2.9) 8 (3.2)
Geniculate Neuralgia 1 (0.3) 0 (0.0)
Musculoskeletal pain (Temporomandibular Disorders; TMD)
Pain-related TMD
Myalgia 69 (19.7) 51 (20.5)
Arthralgia 3 (0.9) 2 (0.8)
Mixed (myalgia and arthralgia) 4 (1.1) 3 (1.2)
TMJ intra-articular disorders
Disc Displacement with/without Reduction 34 (13.7) 15 (14.9)
Neurovascular pain (Headache Disorders)
Trigeminal Autonomic Cephalgia
Unspecified 3 (0.9) 3 (1.2)
Cluster Headache 1 (0.3) 0 (0.0)
SUNCT 4 (1.1) 4 (1.6)
SUNA 1 (0.3) 1 (0.4)
Paroxysmal Hemicrania 2 (0.6) 1 (0.4)
Hemicrania Continua 10 (2.9) 8 (3.2)
Migraine 59 (16.9) 41 (16.5)
Other Primary/Secondary Headaches 45 (12.9) 31 (12.4)
Idiopathic pain
Persistent Idiopathic Facial Pain 5 (1.4) 3 (1.2)
No diagnosis (or provisional only) 4 (1.1) 3 (1.2)
Other (Bodily) Chronic Pain 75 (25.2) 53 (25.2)
Comorbid Medical Condition(s) 118 (39.6) 89 (42.6)
Note: Age and time since onset data were available for 349 (249) and 310 (223) patients, respectively; data concerning site affected and symptom 
laterality were available for 342 (239) and 335 (241) patients, respectively; data concerning body pain and comorbid medical condition were available 
for 298 (210) patients; percentages reflect the proportions from available data only; diagnoses are not mutually exclusive across patients—98 
(28.0%) and 71 (28.5%) patients had received more than one diagnosis in the total cohort and questionnaire completer subsample, respectively—
as such, percentages in each column do not add up to 100%; TMJ = Temporomandibular Joint; SUNCT = Short-Lasting Unilateral Neuralgiform 
Headache Attacks with Conjunctival Injection and Tearing; SUNA = Short-Lasting Unilateral Neuralgiform Headache Attacks with Cranial Autonomic 
Symptoms; Other Primary/Secondary Headaches includes tension-type headache; Co-medical conditions included (but were not limited to) 
hypertension, diabetes, hypothyroidism, multiple sclerosis, epilepsy, hiatus hernia, cardiovascular disease and/or malignancy.
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and psychological disability (difficulty to relax, embarrassment) were 
the domains most often highlighted by patients. EQ-5D-5L health 
state valuation scores suggested overall health was compromised in 
patients in comparison with age-matched healthy UK populations.23 
Patients evidenced significant pain catastrophizing; the group mean 
markedly higher than that observed in a large nonclinical sample.25 
Self-efficacy for coping with pain was, on average, in the mid-range, 
although more than a third (37.7%) scored 30 or less, indicating low 
confidence.
3.4 | Impact of neuropathic, musculoskeletal and/or 
neurovascular on psychosocial function
The associated risk of reporting experienced orofacial pain at the 
time of consultation was more than three times greater in pa-
tients with neurovascular symptoms (OR = 3.39, CI = 1.46, 7.90), 
with no significant effect of either neuropathic (P = .574) or mus-
culoskeletal symptoms (P = .727). There were also significant ef-
fects of neurovascular symptoms on VAS pain, PSEQ scores and 
EQ-VAS (Table 3), reflecting higher levels of pain, decreased pain 
self-efficacy and poorer health, respectively, in those with neuro-
vascular symptoms. By contrast, there were highly significant ef-
fects of neuropathic symptoms on OHIP-14 scores, indicative of a 
greater cost of these symptoms to oral health. Affective function 
was not related to OFP symptom type, including PHQ-9 suicidal 
ideation (for all symptom types, P > .350). Significant effects re-
mained after FDR correction and in subsequent (GLM regression) 
analyses that also controlled for VAS pain, except for neurovas-
cular symptoms on pain self-efficacy (P = .102). Post hoc analyses 
showed moderate-to-severe levels of VAS pain were significantly 
more likely in patients with neurovascular symptoms (79.7%) than 
those without (57.9%; OR = 2.85, CI = 1.47, 5.54, P = .002) and 
significant differences between patients with and without neu-
ropathic symptoms (after controlling for VAS pain severity) on 
functional limitation, psychological discomfort, psychological 
disability, social disability and handicap subscales of the OHIP-14 
(Figure 2).
3.5 | Impact of multiple OFP symptoms
There were significant differences between those with and without 
multiple OFP symptom types for VAS pain (M = 5.70, SD = 2.54 ver-
sus M = 4.54, SD = 3.12, P = .007) and EQ-VAS (M = 59.65, SD = 24.87 
versus M = 69.51, SD = 22.66, P = .006), with all other measures non-
significant (P > .138). However, once presence of neurovascular pain 
was accounted for (Figure 3), the effects of multiple OFP symptom 
types on VAS pain and EQ-VAS were no longer significant (for both, 
P > .102). There was also no interaction between neurovascular pain 
F I G U R E  1   Number of patients (completing functional measures 
in parentheses) with neuropathic, musculoskeletal and/or 
neurovascular orofacial symptoms (n = 342)
TA B L E  2   Affective function, health-related quality of life 
(HRQoL) and pain severity and behaviour in patients with orofacial 
pain
n Mean (SD)
VAS pain (0-10) 233 4.81 (3.03)
Mood
PHQ-9 (0-27) 196 5.25 (6.72)
Suicidal ideation (Item 9; 0-3) 195 0.17 (0.53)
GAD-7 (0-21) 210 6.99 (6.32)
HRQoL measures
OHIP-14 Severity (0-56) 235 25.25 (15.05)
Functional limitation (0-8) 234 2.41 (2.51)
Physical pain (0-8) 238 5.20 (2.58)
Psychological discomfort 
(0-8)
233 4.52 (2.84)
Physical disability (0-8) 239 2.91 (2.70)
Psychological disability (0-8) 236 3.78 (2.58)
Social disability (0-8) 237 3.28 (2.76)
Handicap (0-8) 238 3.27 (2.61)
OHIP-14 Extent (0-14) 235 5.09 (4.15)
EQ-Health (−0.285 to 1.00) 234 0.665 (0.276)
EQ-VAS (0-100) 237 67.26 (23.49)
Pain behaviours
PCS (0-52) 153 23.75 (14.48)
PSEQ (0-60) 162 35.43 (16.43)
Note: n values for questionnaires are variable due to a small number of 
patients not completing all measures.
VAS Pain = pain severity rating at consultation; PHQ-9 = Patient Health 
Questionnaire – 9; GAD-7 = Generalized Anxiety Disorder - 7; OHIP-
14 = Oral Health Impact Profile-14; EQ-Health = EQ-5D-5L health 
state evaluation; EQ-VAS = current overall health rating; PCS = Pain 
Catastrophizing Scale; PSEQ = Pain Self-Efficacy Questionnaire.
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and multiple symptom types for VAS pain (P = .894). A significant 
interaction between neurovascular pain and multiple OFP symp-
tom types for EQ-VAS was observed (B=−23.95, CI=−44.42,-3.47, 
P = .022); however, reflecting worse reported health for patients 
with neurovascular pain and (comorbid) neuropathic/musculoskel-
etal OFP compared with patients with only neurovascular symp-
toms. Interestingly, after accounting for the presence of TMD pain 
on (presence of) comorbid body pain (which was highly significant 
(OR=3 .39, CI =1.68,6.87, P = .001)), there was no main effect of 
multiple OFP symptoms on comorbid body pain nor any significant 
interaction between TMD and multiple symptom type (for both, 
P > .515).
4  | DISCUSSION
The present study systematically measured HRQoL, psychological 
function and pain experience in a large sample of patients with (co-
existing) musculoskeletal, neuropathic and/or neurovascular OFP. 
Overall, the study demonstrated a substantial patient burden result-
ing from OFP. The findings indicate that patients with neurovascular 
symptoms presented with higher pain levels, had lower health rat-
ings and less pain self-efficacy, while patients with neuropathic pain 
experienced greater functional, social and psychological oral health 
disability.
A high proportion of patients attending the clinic presenting with 
headache disorders had comorbid musculoskeletal OFP, and less fre-
quently, comorbid neuropathic OFP, consistent with the observed 
interrelations between these disorders. The comorbidity of head-
ache disorders with TMD is particularly well established, a likely con-
sequence of overlapping nociceptive systems, peripheral and central 
sensitization processes in the trigeminal system common to both, 
and/or shared genetic risk.9,11 The relationship between neuropathic 
OFP and neurovascular symptoms is less well understood, although 
common pathophysiological mechanisms bridging relevant condi-
tions, such as deregulation of myelination and axonal abnormalities 
of the trigeminal nerve in TN and migraine, have been proposed.12
In line with well-established findings that chronic headache dis-
orders have a substantial impact on mood and HRQoL3 and previ-
ous studies of OFP populations indicating that patients presenting 
with headache disorders are particularly vulnerable to anxiety and 
depressive disorders and a high degree of disability,9,14 we observed 
a profound impact of neurovascular pain on patient well-being. 
Interestingly, previous OFP studies have focussed on the differ-
ential impact of comorbid TMD and neurovascular pain, reporting 
significantly greater pain intensity and psychosocial and health im-
pairments than with singular disturbances.14,15,28 In this study, the 
presence of neurovascular symptoms in OFP patients was associ-
ated with significantly greater pain levels, poorer VAS health rat-
ings and lower self-efficacy to cope with pain relative to TMD or 
neuropathic pathology—that is, patients with chronic headache dis-
orders had poorer function irrespective of whether they were also 
diagnosed with TMD or a neuropathic OFP condition. On a clinical 
level, this highlights the critical relevance of neurovascular pain to 
the health and functioning of patients presenting in OFP clinics, and, 
more generally, the importance of specialist neurologists’ input in 
TA B L E  3   Impact of musculoskeletal, neuropathic and neurovascular symptoms on affective function, HRQoL, and pain severity and 
behaviour in patients with orofacial pain
Questionnaire
Neuropathic Musculoskeletal Neurovascular
B (CI) P B (CI) P B (CI) P
VAS pain (0-10) −0.34 (−1.41, 0.74) .523 0.40 (−0.57, 1.38) .431 1.27 (0.41, 2.11) .005
Mood
PHQ-9 (0-27) −1.67 (−4.72, 1.42) .268 −1.63 (−4.23, 0.94) .210 0.98 (−1.57, 3.62) .451
GAD-7 (0-21) −1.74 (−4.36, 0.88) .192 0.28 (−2.19, 2.74) .825 1.50 (−0.55, 3.55) .152
HRQoL measures
OHIP-14 Severity (0-56) 8.24 (2.35, 14.12) .006 4.11 (−1.38, 9.61) .143 3.06 (−1.64, 7.77) .202
OHIP-14 Extent (0-14) 2.28 (0.66, 3.90) .006 0.91 (−0.60, 2.43) .237 0.96 (−0.33, 2.26) .145
EQ-Health (−0.285 - 1.00) 0.023 (−0.088,0.133) .689 −0.018 (−0.122, 0.085) .729 -0.036 (−0.122, 0.051) .423
EQ-VAS (0-100) −1.57 (−10.73, 7.59) .737 −2.51 (−11.11, 6.08) .566 −11.81 (−19.01, −4.60) .001
Pain behaviours
PCS (0-52) 1.11 (−5.65, 7.75) .724 1.71 (−4.37, 7.61) .550 4.03 (−1.58, 9.66) .160
PSEQ (0-60) −0.04 (−7.37, 7.30) .992 −0.51 (−7.38, 6.34) .883 −6.77 (−12.79, −0.76) .027
Note: n values for questionnaires are variable due to a small number of patients not completing all measures; Unstandardized beta values (B) 
and associated 95% confidence intervals (CI) and P values were calculated using generalized linear models (GLM) with presence of neuropathic, 
musculoskeletal and neurovascular symptoms entered in as independent variables; VAS Pain = pain severity rating at consultation; PHQ-9 = Patient 
Health Questionnaire – 9; GAD-7 = Generalized Anxiety Disorder - 7; OHIP-14 = Oral Health Impact Profile-14; EQ-Health = EQ-5D-5L health state 
evaluation; EQ-VAS = current overall health rating; PCS = Pain Catastrophizing Scale; PSEQ = Pain Self-Efficacy Questionnaire; significant effects of 
symptom type are highlighted in bold.
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assessment, diagnosis and management of patients attending OFP 
clinics as part of a multidisciplinary approach.8
Despite clear differences in sensory aspects of their pain, pa-
tients with musculoskeletal OFP experienced levels of psychological 
(dys)function and impaired HRQoL comparable to those with neu-
ropathic OFP, consistent with previous studies.4,5 A number of oral 
health domains were more affected by the presence of neuropathic 
symptoms than by TMD (or neurovascular pain), however, reflecting 
that aspects of oral HRQoL critically involved with social interac-
tions, such as speech, eating and drinking, are particularly problem-
atic for patients with neuropathic OFP.13
Surprisingly, multiple OFP symptoms were a poor predictor of 
psychosocial function, at least once the presence of neurovascular 
pain was accounted for. Nevertheless, we found reported health was 
worse in patients with neurovascular disorders who had comorbid 
TMD or neuropathic symptoms than those without. It is possible, at 
least for patients with musculoskeletal pain, that this finding merely 
reflects the increased severity of (comorbid) disorders as both se-
verity and frequency of headache have been linked with TMD 
symptoms.16 However, pain severity at consultation did not differ 
between neurovascular disorder patients with and without comor-
bid (musculoskeletal) symptoms and the presence of headache in 
TMD patients has been shown to dramatically increase the associ-
ated risk of depression and high disability even after controlling for 
severity of TMD,15 suggesting headache combined with other types 
of OFP may pose an increased risk of poor health and disability.
There was a significant risk of OFP patients with TMD symp-
toms reporting comorbid chronic body pain. This is consistent with 
reports that TMD symptoms exhibit significant statistical overlap 
with other chronic pain conditions.10 Interestingly, while research 
has suggested headache in TMD patients is associated with a 
greater number of bodily pain conditions compared to TMD without 
headache,28 we observed no effect of multiple OFP symptoms on 
body pain in TMD patients. Rather, the presence of (chronic) body 
pain was more likely in TMD patients irrespective of whether or 
not they also experienced neurovascular pain, consistent with ev-
idence of dysregulation in central pain pathways in some patients 
with TMD.29
There were some important study limitations. First, while included 
patients had all been subject to clinical examination and received for-
mal OFP diagnoses, and we did consider pain severity at consulta-
tion, we did not consider other indications of severity of symptoms 
for specific conditions, such as headache frequency/combinations 
in those with neurovascular pain, which are likely to influence pa-
tient-reported outcomes. Second, patients were grouped together 
by broad symptom-based classifications, each encompassing several 
conditions with different aetiologies, and within-group differences 
in measured constructs are likely. For example, differences in HRQoL 
or psychological distress have been observed between TMD patients 
with and without combination headaches16 and between patients 
with TN and PTTN.13 Third, the cross-sectional design does not 
allow causal relationships between OFP disorders and patients’ pres-
ent functioning to be established—this is important considering that 
psychological dysfunction can increase the risk of OFP,30 suggesting 
F I G U R E  2   Mean scores on OHIP-14 domains for patients 
with and without neuropathic orofacial symptoms. Error bars 
represent 95% confidence intervals; n values for subscales are 
slightly variable due to missing responses on some OHIP-14 items; 
*Indicates significant differences between groups after controlling 
for VAS pain severity (*P < .05; **P < .01; ***P < .001)
F I G U R E  3   Mean VAS pain and EQ-VAS 
(“health today”) scores for patients with 
and without neurovascular pain according 
to whether or not they have multiple 
orofacial symptoms. Error bars represent 
95% confidence intervals
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a reciprocal relationship. Finally, the sample is unlikely to be reflec-
tive of the typical OFP population given the over-representation of 
patients with neuropathic pain conditions (clinic speciality) and that 
those individuals seeking treatment are more likely to exhibit psy-
chological dysfunction and greater disability.
In conclusion, this study suggests a substantial burden of chronic 
OFP in patients attending a tertiary OFP clinic, the extent to which 
differs according to the presenting class of symptoms, with neuro-
vascular pain the most impactful on pain severity and overall health, 
and neuropathic symptoms more closely linked with oral health-re-
lated functional and psychological impairments. Future prospective 
studies may establish the extent to which OFP symptom types relate 
to long-term outcomes of patients, particularly in individuals with 
complex symptom presentations.
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